OTCMKTS:MRMD

MariMed (MRMD) Stock Price, News & Analysis

MariMed logo
$0.05 +0.00 (+3.67%)
As of 02:50 PM Eastern

About MariMed Stock (OTCMKTS:MRMD)

Advanced

Key Stats

Today's Range
$0.05
▼
$0.06
50-Day Range
$0.05
▼
$0.08
52-Week Range
$0.05
▼
$0.16
Volume
498,261 shs
Average Volume
584,686 shs
Market Capitalization
$20.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

MariMed, Inc. is a U.S. cannabis company that cultivates, processes, manufactures and sells cannabis products for medical and adult-use markets. Its operations include cultivation and production facilities as well as retail dispensaries in multiple states.

The company offers cannabis flower, concentrates, edibles and other products through brands including Nature’s Heritage, Betty’s Eddies and Bubby’s Baked. Its dispensaries sell products to consumers in the markets where MariMed operates.

MariMed traces its roots to the early 2010s, when it began providing management and operational services to cannabis businesses before expanding into owning and operating cannabis operations. Its business is focused on serving state-regulated markets in the United States.

AI Generated. May Contain Errors.

MariMed Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
9th Percentile Overall Score

MRMD MarketRank™: 
0.466008771925 of 5 stars

MariMed scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MariMed has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    MariMed has received no research coverage in the past 90 days.

  • Read more about MariMed's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MariMed is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MariMed is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MariMed has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.01% of the float of MariMed has been sold short.
  • Short Interest Ratio / Days to Cover

    MariMed has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MariMed has recently increased by 1,748.60%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    MariMed does not currently pay a dividend.

  • Dividend Growth

    MariMed does not have a long track record of dividend growth.

  • Search Interest

    1 people have searched for MRMD on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MariMed insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.05% of the stock of MariMed is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    0.18% of the stock of MariMed is held by institutions.

  • Read more about MariMed's insider trading history.
Receive MRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MRMD Stock News Headlines

MariMed Reports Third Quarter 2026 Earnings
This Could Be the Biggest Monetary Shift in 50 Years
The U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trades above $4,000 today. That gap means Washington's books show about $11 billion in gold that is actually worth more than $1 trillion. A bill in Congress would require repricing those reserves at market value. More than 60 million Americans qualify to move part of their savings into physical gold, tax-free and penalty-free, according to the 2026 Gold and Silver Guide.tc pixel
MariMed Q3 earnings preview
MariMed (MRMD) Projected to Post Quarterly Earnings on Wednesday
See More Headlines

MRMD Stock Analysis - Frequently Asked Questions

MariMed's stock was trading at $0.0879 at the start of the year. Since then, MRMD shares have decreased by 42.2% and is now trading at $0.0508.

MariMed Inc. (OTCMKTS:MRMD) issued its quarterly earnings data on Wednesday, November, 11th. The company reported ($0.01) EPS for the quarter, meeting analysts' consensus estimates of ($0.01). The business had revenue of $44.23 million for the quarter, compared to analyst estimates of $41.20 million. MariMed had a negative trailing twelve-month return on equity of 13.19% and a negative net margin of 9.27%.
Read the conference call transcript
.

Shares of MRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MariMed investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), Curaleaf (CURLF), Charlotte's Web (CWBHF), MedMen Enterprises (MMNFF) and Organigram Global (OGI).

Company Calendar

Last Earnings
11/11/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Healthcare Equipment & Supplies
Sub-Industry
N/A
Current Symbol
OTCMKTS:MRMD
Previous Symbol
OTC:MRMD
CIK
1522767
Fax
N/A
Employees
866
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.48 million
Net Margins
-9.27%
Pretax Margin
-6.42%
Return on Equity
-13.19%
Return on Assets
-2.97%

Debt

Debt-to-Equity Ratio
1.90
Current Ratio
0.90
Quick Ratio
0.34

Sales & Book Value

Annual Sales
$159.83 million
Price / Sales
0.13
Cash Flow
$0.02 per share
Price / Cash Flow
2.42
Book Value
$0.10 per share
Price / Book
0.51

Miscellaneous

Outstanding Shares
402,950,000
Free Float
338,281,000
Market Cap
$20.47 million
Optionable
Not Optionable
Beta
1.54
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (OTCMKTS:MRMD) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners